SG11202100665WA - Crystal form of lanosterol prodrug compound and application thereof - Google Patents

Crystal form of lanosterol prodrug compound and application thereof

Info

Publication number
SG11202100665WA
SG11202100665WA SG11202100665WA SG11202100665WA SG11202100665WA SG 11202100665W A SG11202100665W A SG 11202100665WA SG 11202100665W A SG11202100665W A SG 11202100665WA SG 11202100665W A SG11202100665W A SG 11202100665WA SG 11202100665W A SG11202100665W A SG 11202100665WA
Authority
SG
Singapore
Prior art keywords
application
crystal form
prodrug compound
lanosterol prodrug
lanosterol
Prior art date
Application number
SG11202100665WA
Other languages
English (en)
Inventor
Yizhi Liu
Yandong Wang
Xiaolin Li
Zhi Luo
Haiying He
Jian Li
Shuhui Chen
Original Assignee
Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd filed Critical Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Publication of SG11202100665WA publication Critical patent/SG11202100665WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
SG11202100665WA 2018-07-25 2019-07-25 Crystal form of lanosterol prodrug compound and application thereof SG11202100665WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810826425 2018-07-25
PCT/CN2019/097773 WO2020020306A1 (zh) 2018-07-25 2019-07-25 一种羊毛甾醇前药化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
SG11202100665WA true SG11202100665WA (en) 2021-02-25

Family

ID=69180373

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100665WA SG11202100665WA (en) 2018-07-25 2019-07-25 Crystal form of lanosterol prodrug compound and application thereof

Country Status (16)

Country Link
US (1) US11149055B2 (ja)
EP (1) EP3828193A4 (ja)
JP (1) JP7046266B2 (ja)
KR (1) KR20210038596A (ja)
CN (1) CN112543762B (ja)
AU (1) AU2019308940B2 (ja)
BR (1) BR112021001172A2 (ja)
CA (1) CA3107361C (ja)
CO (1) CO2021000932A2 (ja)
MA (1) MA53397A (ja)
MX (1) MX2021000900A (ja)
PH (1) PH12021550182A1 (ja)
RU (1) RU2766088C1 (ja)
SG (1) SG11202100665WA (ja)
WO (1) WO2020020306A1 (ja)
ZA (1) ZA202100923B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220133744A1 (en) * 2019-03-04 2022-05-05 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Composition of lanosterol prodrug compound, preparation method therefor and use thereof
KR20240046546A (ko) * 2021-08-18 2024-04-09 광저우 오쿠순 옵탈믹 바이오테크놀로지 캄파니 리미티드 스테로이드의 비문증 예방 및/또는 치료 약물 제조에 있어서의 용도
AU2022329224A1 (en) * 2021-08-18 2024-03-21 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Pharmaceutical composition, preparation method therefor and application thereof
CN115737654A (zh) * 2021-09-03 2023-03-07 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
WO2023143452A1 (zh) * 2022-01-28 2023-08-03 广州润尔眼科生物科技有限公司 甾体化合物在预防和/或治疗白内障中的应用
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757062A (en) 1985-11-01 1988-07-12 E. I. Du Pont De Nemours And Company Substituted benzoate ester prodrugs of estrogens
DE3540702A1 (de) 1985-11-16 1987-05-21 Bayer Ag 1h-pyrido-(2,3-b) (1,4)-thiazine
RU2283318C1 (ru) * 2005-02-24 2006-09-10 Любовь Степановна Ермолова Способ производства стеринов: ланостерола и холестерола из шерстного жира
EP3182977B1 (en) * 2014-08-22 2021-05-05 The Regents Of The University Of California Lanosterol for use in treating vision disorders
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
DK3536698T3 (da) * 2017-01-25 2021-09-27 Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd Lanosterol-prodrugforbindelse og anvendelse deraf

Also Published As

Publication number Publication date
CA3107361C (en) 2022-03-22
EP3828193A4 (en) 2022-06-29
KR20210038596A (ko) 2021-04-07
ZA202100923B (en) 2021-10-27
JP2021524499A (ja) 2021-09-13
CN112543762A (zh) 2021-03-23
EP3828193A1 (en) 2021-06-02
CO2021000932A2 (es) 2021-02-17
JP7046266B2 (ja) 2022-04-01
BR112021001172A2 (pt) 2021-04-27
CN112543762B (zh) 2022-11-08
RU2766088C1 (ru) 2022-02-07
PH12021550182A1 (en) 2022-02-21
AU2019308940B2 (en) 2024-02-08
MX2021000900A (es) 2021-06-15
CA3107361A1 (en) 2020-01-30
WO2020020306A1 (zh) 2020-01-30
AU2019308940A1 (en) 2021-03-11
US20210246158A1 (en) 2021-08-12
MA53397A (fr) 2021-06-02
US11149055B2 (en) 2021-10-19

Similar Documents

Publication Publication Date Title
ZA202100923B (en) Crystal form of lanosterol prodrug compound and application thereof
IL279468A (en) Crystallographic modifications of odeviccibat
IL273831A (en) Crystal forms and preparations of CFTR modulators
IL284508A (en) Irreversible inhibitors of the MENIN-MLL interaction
ZA201904124B (en) Lanosterol prodrug compound and preparation method therefor and use thereof
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
SG11202103134TA (en) Nitroxoline prodrug and use thereof
IL285117A (en) Methods for characterizing properties related to condensation of compounds and their uses
PT3867446T (pt) Composições de adesivo yankee e métodos de utilização destas composições
EP3858346A4 (en) USE OF CHIGLITAZAR AND RELATED LINKS THEREOF
IL285219A (en) A crystal of the compound diarylthiohydantoin
ZA202101589B (en) Crystal form of tri-cycle compound and application thereof
EP3816156A4 (en) RADIOACTIVE COMPOUND FOR THE TREATMENT OF MELANOMA AND USE THEREOF
GB2574223B (en) Adhesives and methods of forming adhesives
EP3687514A4 (en) METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3
IL263868A (en) Crystal structures of aminomethyl-converted tetracyclines and processes for their preparation
EP3608306A4 (en) CRYSTALLINE FORM AND AMORPHIC FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE
GB2589398B (en) Compounds and methods of use
IL283703A (en) A polymorphic form of meisoindigo and a different formulation of meisoindigo
SG11202009262VA (en) Salts of compounds and crystals thereof
SG11202105136WA (en) Application of chidamide
EP3619193A4 (en) AMINOARYL BENZAMIDE COMPOUNDS AND METHOD OF USING THEREOF
EP3819297A4 (en) CRYSTAL FORMS OF THE THIAZOLE COMPOUND AND APPLICATIONS THEREOF
EP4067346A4 (en) CRYSTALLINE FORM OF QUINOLINONE COMPOUND AND ITS USE
EP3845534A4 (en) SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF